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Available online 3 September 2011Protein phosphorylation by kinases plays a central role in the regulation and coordination
of multiple biological processes. In general, knowledge on kinase specificity is restricted
to substrates identified in the context of specific cellular responses, but kinases are likely
to have multiple additional substrates and be integrated in signaling networks that might
be spatially and temporally different, and in which protein complexes and subcellular
localization can play an important role. In this report the substrate specificity of atypical
human vaccinia-related kinases (VRK1 and VRK2) using a human peptide-array containing
1080 sequences phosphorylated in known signaling pathways has been studied. The two ki-
nases identify a subset of potential peptide targets, all of them result in a consensus se-
quence composed of at least four basic residues in peptide targets. Linear peptide arrays
are therefore a useful approach in the characterization of kinases and substrate identifica-
tion, which can contribute to delineate the signaling network in which VRK proteins partic-
ipate. One of these target proteins is coilin; a basic protein located in nuclear Cajal bodies.
Coilin is phosphorylated in Ser184 by both VRK1 and VRK2. Coilin colocalizes and interacts
with VRK1 in Cajal bodies, but not with themutant VRK1 (R358X). VRK1 (R358X) is less active
than VRK1. Altered regulation of coilin might be implicated in several neurological diseases
such as ataxias and spinal muscular atrophies.
© 2011 Elsevier B.V.Open access under CC BY-NC-ND license. Keywords:
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Most biological processes are regulated by reversible phos-
phorylation, and kinases play a central role in signal trans-
mission, and coordination of interacting signaling pathways,
which regulate multiple biological processes in mammaliane; VCP, valosin-containing
m.
estigación del Cáncer, CSI
34 923 294 795.
azo).
CC BY-NC-ND license. cells. The elucidation of the human kinome [1] due to its po-
tential for pharmacologic targeting has opened up new possi-
bilities to characterize and develop strategies to manipulate
these regulatory processes with therapeutic aims, and of
which targeting receptor tyrosine kinase is currently the para-
digm of this approach [2]. This has generated a great interestprotein; SMN1, survival of motor neuron 1; SMA, spinal muscular
C- Universidad de Salamanca, CampusMiguel de Unamuno, E-37007
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Several approaches have been used to determine kinase
specificity ranging from phosphorylation databases [3], artifi-
cial neural networks [4–6], and large peptide screening [7].
VRK1 and VRK2 play a role in controlling cell division pro-
cesses [8–10]. VRK1 and VRK2 are two novel Ser–Thr kinases
belonging to a unique and isolated subfamily with only three
members in the human kinome [1]. VRK1 and VRK2 have a
common catalytic domain with an identity of 64%, and an
80% homology [11,12]. In addition the VRK proteins have
unique amino acid substitutions suggesting they might be
pseudokinases [11]. However, VRK1 [13] and VRK2 [11] [14]
have been demonstrated to be catalytically active. VRK3,
which is the most divergent of the three VRK proteins, is cata-
lytically inactive [11]. Interestingly, the activity of VRK1 and
VRK2 proteins has been shown to be regulated by protein-
protein interactions; both are active when bound to RanGTP,
and inactive when bound to RanGDP [15]. This indicates that
these two kinases have two alternative conformations that
can be allosterically regulated [15]. VRK1 is a nuclear kinase
[11,13], while VRK2 has two isoforms, a full-length protein of
508 amino acids (VRK2A) [11], which is anchored to cytosolic
organellemembranes, such as endoplasmic reticulum andmi-
tochondria by its C-terminal hydrophobic region [14]; and iso-
form VRK2B with 397 amino acids lacking the C-terminal
region, which is located in both cytosol and nuclei, perhaps
functionally replacing in some aspects VRK1, and is detected
only in some cellular types, like adenocarcinomas [14]. The
conservation in catalytic domain suggests that substrate utili-
zation, and perhaps specificity, might be determined by either
protein complexes or subcellular localization, and thus it may
generate a signal compartmentalization [16].
More recently the use of peptide chips representing known
phosphorylated proteins, which have been validated and in-
cluded in Phosphobase [17,18], has become feasible [19].
These peptide chips have been successfully used in different
proteome studies to identify the phosphorylated targets in re-
sponse to lypolysaccharides in monocytes [19], substrates of
c-src [20] and of the KPI-2 Ser–Thr kinase [21], detection of dif-
ferential specificity of c-Raf and MAP3K8 Ser–Thr kinases [22],
and identification of Lck and Fyn tyrosine kinases as targets of
glucocorticoid activation [23].
Up to now some substrates have been identified which are
common to both VRK proteins, such as p53 [13,24] or c-Jun
[25]. The specific and unique phosphorylation of p53 in
Thr18 is the best characterized substrate, which is common
to both VRK1 and VRK2A and VRK2B, although VRK1 appears
to be its main regulator in vivo [8,26,27], identifying a novel
autoregulatory loop [28]. In addition membrane bound
VRK2A seems to participate in large signaling complexes
with scaffold proteins, which can determine signal magnitude
and specificity, and modulating signal transmission by MAPK
in response to interleukin 1β [29], hypoxia [30] or growth fac-
tors [31]. Therefore, in this work we have aimed to determine
if catalytically active VRK1 and VRK2 proteins have similar or
different substrate specificity. The use of pepchip kinase as-
says has been useful to identify substrates for a variety of pro-
teins, and although it is possible that linear peptides may
have a different configuration in a complete protein, many
of them also appear to be substrates in the complete protein[19]. Therefore, we have applied this experimental approach
to the identification of novel substrates for the active mem-
bers of the vaccinia-related kinase family, VRK1 and VRK2.
One of the substrates identified for nuclear VRK1 proteins is
coilin, which interacts and is phosphorylated by VRK1. Coilin
is a candidate protein regulated by phosphorylation that
might be implicated in several neurodegenerative diseases
[32,33]. We have also compared the wild-type VRK1 with the
only knownmutant reported in humans, R358X, which causes
a neurological syndrome in children causing a spinal ponto-
cerebellar degeneration with ataxia, spinal muscular atrophy
and infant death [34], and the effect on coilin may be defective
in these patients.2. Materials and methods
2.1. Plasmids and expression of proteins
Human VRK1was expressed from plasmids pGEX4T-VRK1 [13]
and pET23-His-VRK1 [15] and purified using Glutathione–
Sepharose (GE Healthcare) or Talon resin (BD Biosciences,
Palo Alto, CA). VRK2A and VRK2B were expressed form plas-
mids pGEX4T-VRK2A and pGEX4T-VRK2B respectively [14].
GST fusion proteins were eluted with glutathione, and His
tagged proteins with imidazole from the corresponding resin
[13,15]. Protein purification was checked in a 10% PAGE [35].
The GST moiety of fusion proteins was detected with an
anti-GST antibody (sc-138) from Santa Cruz. VRK1 was
detected with either a polyclonal or monoclonal antibody
[35]. Cells transfected with empty vector were used as control.
The following plasmid mammalian expression clones were
used: pCEFL-GST-VRK1, pCEFL-GST-VRK1-KD, pCEFL-HA-
VRK1, pCEFL-HA-VRK1-KD were previously reported [25,36].
Plasmids pCEFL-HA-VRK1(R358X), pGEX-4T-VRK1(R358X) and
pET23-His-VRK1(R358X) contain the human VRK1 mutation
R358X introduced using the Quick mutagenesis kit (Strata-
gene, San Diego, CA); pCMV6-Myc-DKK-coilin, was from Ori-
gene (Rockville, MD). These plasmids were expressed in 293T
cells and immunoprecipitated with an anti myc epitope poly-
clonal (06-549) or monoclonal (06-724) antibody both from
Millipore. The DKK epitope was detected with an anti-FLAG
antibody from Sigma. The human coilin cDNA obtained from
OriGene (Rockville, MD) was amplified by PCR and subcloned
in pGEX4T′, the resulting clone (pGEX4T-coilin) was confirmed
by DNA sequencing. These pCMV6-Myc-DKK-Coilin and
pGEX4T-coilin clones were used to generate the S183A muta-
tion with the Quick-change mutagenesis kit (Stratagene).
The bacterially expressed GST-p53 (1-85) has been previously
reported [13].
2.2. Cell culture and transfections
The HEK-293T and HeLa cell lines were grown in DMEM sup-
plemented with 10% fetal bovine serum, 2 mM glutamine
and antibiotics in a humidified 5% CO2 atmosphere at 37 °C.
For transient transfections, 106 HEK-293T cells were grown in
P100 dishes and transfected 24 hours later with JetPI reagent
according to the manufacturer's recommendations (Poly-
transfection, Ilkirch, France).
550 J O U R N A L O F P R O T E O M I C S 7 5 ( 2 0 1 1 ) 5 4 8 – 5 6 02.3. Peptide array chip kinase assay and analysis
The characteristic of the peptide array is described in the
web page of its manufacturer Pepscan Presto (Lelystad, The
Netherlands) has already been successfully used and validated
in several studies [19–23]. The microarray contains 1024 pep-
tides (48 controls, 976 experimental), (PCKINOM01) in triplicate
per slide was from Pepscan Presto (Lelystad, The Netherlands)
(Supplemental Table S1) [22]. All peptides in the chip represent
1024 signaling proteins whose phosphopeptides have been ex-
perimentally identified, all are related with stress, growth and
differentiation signaling, and are included in the PhosphoELM
database [17,18]. The successful application of this peptide
chip with other kinases has already been reported [21,22,37].
Briefly, in each kinase assay 250 ng of the corresponding puri-
fied kinase was used in a reaction buffer containing 60mM
HEPES pH 7.4, 10mM MgCl2, 10mM MnCl2, 0.05% BSA, 5.3%
glycerol and 267 μCurie/ml [32P-γ]ATP in a final volume per
chip of 80 μl. Incubation was performed for 2 h at 37 °C. The
slides were washed with PBS containing 0.1% Triton X-100,
nextwith 2 MNaCl and finallywith demineralizedH2O followed
by drying under N2. The radioactive signals on dried glass slides
were detectedusing a phosphor-imager (Storm, AmershamBio-
sciences). Array scans were quantified using standard quantifi-
cation software (Quantity One, BioRad) and the Scanalyze
program (http://rana.lbl.gov/EisenSoftware.htm) and exported
to an Excel spreadsheet (Microsoft Corp. Redmont, WA). The
complete datasets and values are listed in the accompanying
content lists of the array (Supplemental Table S2). Based on
this information, four topscore lists were generated for the
each enzyme as shown in the worksheet. The complete data
for all peptides in presented in Table S2. The top 30 strongest
phosphorylated peptides are shown in the Results section.
2.4. In vitro kinase assay of candidate proteins
To assay coilin phosphorylation by VRK1 kinase, coilin-myc and
coilin(S184A)-myc used in kinase assays were purified from
HEK-293T cell extracts by immunoprecipitation. Immunopre-
cipitations were performed as described below with the follow-
ing modifications: For each kinase assay reaction, 2×106
HEK293T cells were transfected with 5 μg of plasmid coilin-
myc, coilin(S184A)-myc or empty vector. Cell lysates (up to
3mg/ml) were clarified and incubated with α-myc monoclonal
antibody (Millipore) for 2 h. Then, NaCl concentration of extracts
was raised to 500mM. Each sample was incubated with 40 μl of
gamma bind beads (GE Healthcare) for 2 h and beads were ex-
tensively washed with 500 mM NaCl-lysis buffer. A final wash
with PBS was performed. Immunoprecipitated proteins were
stored in PBS-10% glycerol at −20 °C. Kinase assays were per-
formed in a final volume of 65 μl containing VRK kinase buffer
(20 mM Tris–HCl, pH 7.5, 5 mM MgCl2, 0.5 mM dithiothreitol
(DTT), 150 mM KCl), 100 μM ATP and 5 μCi of [32P]ATP[γP]. In
each reaction, 5 μg of GST-VRKprotein andone aliquot of immu-
noprecipitated coilin-myc or coilin(S184A)-myc proteins were
used. The reactions were routinely performed at 30 °C for
30 min [13] and stopped by boiling in Laemmli buffer. The phos-
phorylated proteins were analyzed by electrophoresis in
7.5% SDS-polyacrylamide gels. Proteins were transferred to
Immobilon-P membranes (Millipore) and the incorporatedradioactivity was measured using a Molecular Imager FX
(Bio-Rad, San Diego, CA). When indicated, membranes
were stained with Ponceau staining, or coilin-myc protein
was detected with α-myc antibody in western blots.
Assays with purified GST-VRK1, His-VRK1 or GST-VRK2 and
purified substrates (GST-p53, GST-cJun, GST-ATF2 and Histone
H3) were performed in VRK kinase buffer and 30 μl of final vol-
ume. Proteinswere resolved in SDS-PAGE and gelswere stained
with Coomassie. Activity of GST-VRK1(R358X) was assayed
under the same conditions of GST-VRK1 wild type.
2.5. Western blot analysis, GST pull-down assays, immu-
noprecipitation and antibodies
Cells were harvested 48 h post transfection and lysed with
lysis buffer (1% Triton X-100, 200 mM NaCl, 50 mM Tris, pH
8.0, 1 mM sodium orthovanadate, 1 mM NaF and protease in-
hibitors). 25 μg of total protein lysate was analyzed in SDS-
polyacrylamide gels to check protein expression by Western
blot. For GST pull-down assays, cells were lysed with lysis
buffer and a total of 1 mg of total cell extract was incubated
with Glutathione–Sepharose beads for 4 h at 4 °C. Beads were
washed four times with lysis buffer and analyzed in SDS-
polyacrylamide gels. For endogenous VRK1 or coilin-myc im-
munoprecipitation, cells were lysed with lysis buffer 48 h
after transfection. Clarified cell lysates were subjected to
coilin-myc immunoprecipitation with a monoclonal anti-
myc antibody, or to VRK1 immunoprecipitation with a mix-
ture of polyclonal antibodies VC1 [35] and αVRK1 from Sigma
(HPA000660). Incubations were carried out at 4 °C for 2 h, fol-
lowed by incubation with Gamma-Bind beads (GE Healthcare)
for 2 h. Beads were extensively washed with lysis buffer, pro-
cessed with Laemmli buffer and analyzed by SDS-PAGE. In
western blots, VRK1 protein was detected with monoclonal
1F6 [35] or polyclonal αVRK1 from Sigma. GST was identified
with the monoclonal antibody B14 from Santa Cruz Biotech-
nology. The myc epitope in coilin-myc proteins was detected
with a monoclonal or polyclonal antibody from Millipore.
The secondary antibodies used for western blots anti-
(mouse-HRP) and anti-(rabbit-HRP) were from GE Healthcare.
Luminescence in western blot was developed with an ECL kit
(GE Healthcare). In immunofluorescences, coilin was detected
with the monoclonal antibody Pdelta from Abcam (Cam-
bridge, UK), and VRK1 was detected with a polyclonal anti-
body from Sigma.
2.6. Confocal immunofluorescence microscopy
HeLa orHEK-293T cellswere plated on60mmdishes containing
coverslips and transfected 24 h later when specified. Two days
later, the slideswere collected and cellswere fixed at room tem-
perature with 3% paraformaldehyde for 30min, treated with
200mM glycine for 10min, and then permeabilized with 0.2%
Triton X-100 for 30min at room temperature. A 1% bovine
serum albumin solution in PBS was used to block the cells for
30 min at room temperature. Endogenous Coilin and VRK1 pro-
teins were detected by consecutive immunostaining with the
indicated specific antibodies diluted in blocking solution. Cells
were incubated 1 h at room temperature with each primary an-
tibody, and then with a mixture of the secondary antibodies
Fig. 1 – Chip kinase assay in vitro with different preparations of
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rabbit Cy3-labeled (GE Healthcare) for 1 h at room temperature.
Nuclei were stained with DAPI (Sigma) for 10min at room tem-
perature. Slides were mounted with Gelvatol (Monsanto) and
analyzed with a LEICA SP5 confocal microscope.
2.7. Acid hydrolysis and phosphoamino acid analysis
An in vitro kinase assay was performed with GST-VRK1 and
immunoprecipitated coilin-myc or coilin(S184A)-myc as sub-
strates. The phosphorylated proteins were fractionated by an
SDS-polyacrylamide electrophoresis and transferred to an
Immobilon-P membrane (Millipore, Bedford, MA) and the ra-
dioactive bands corresponding to phosphorylated coilin-myc
and Coilin(S184A)-myc were excised, and proteins were eluted
and hydrolyzed with 200 μl of 6 N HCl at 110 °C for 2 h. Sam-
ples were freeze-dried and resuspended in a mixture contain-
ing 2 μl of a stock solution at 1 mg/ml of P-Ser and P-Thr as
reference markers, 1 μl of 1% bromophenol blue and 2 μl of for-
mic acid/acetic acid/water (1:3.1:35) mix at pH 1.9. The mixture
was applied to a cellulose chromatoplaque (Merck, Darmstadt,
Germany) and subject to flatbed electrophoresis in a Multiphor
II system (Amersham Biosciences, Little Chalfont, UK) at 1.5 kV
for 90min. After air drying, the radioactivity on the chromato-
plaque was analyzed with a Molecular Imager FX (BioRad, San
Diego, CA) or exposed to X-ray film. The phosphoaminoacid
markers were detected by stainingwith a 0.25% ninhydrin solu-
tion in acetone.
2.8. Transcript stability
EBV transformed lymphoblastoid cells were propagated in
RPMI 1640 supplemented with 2 mM glutamine, 10% fetal bo-
vine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, at
37 C with 5% CO2. Genomic DNA was prepared using a stan-
dard salting-out procedure. Total RNA was prepared using
Tri-Reagent (a phenol/guanidine thiocyanate based method,
Molecular Research Center, UK), and reverse transcription
was carried out on 1 μg total RNA using Improm-II (Promega,
USA) with random hexamers in the presence of RNasin
RNase inhibitor (Promega). PCR was performed with Super-
Therm Taq (JMR, UK) for 31 cycles, reactions were cleaned
and sequenced using BigDye terminators v1.1 (Applied Biosys-
tems, ABI) and electrophoresed on an ABI 3130XL Genetic
Analyzer.
2.9. Reagents
All reagents were of analytical grade from Sigma. The nucleo-
tide [32Pγ]ATP was from PerkinElmer/NEN.VRK1 (GST and His tagged) and VRK2A and VRK2B. A. The
phosphorylated spots were detected with a BioRad FX Imager.
In eachslide there are 1024peptides in triplicate. The correlation
of the signals is shown in Table 1. The spotmarkedwith a circle
corresponds to a peptide derived from coilin and containing
residue Ser184. In the left slide the specific detection of the
peptide in triplicate is shown. Horizontally is shown the detec-
tion of the peptide by different VRK protein preparations.
B. Peptide sequence targeted in coilin, indicating the position of
Ser184.3. Results
3.1. Peptide phosphorylation by VRK1 and VRK2A and
VRK2B and substrate identification
The initial approach to identify substrates of the VRK1 and
VRK2 protein kinases was based on the use of linear peptide
chips. Many proteins in mammalian signaling pathways areregulated by phosphorylation and their target sequences are
known. These known mammalian peptide target sequences
were spotted in a slide. Each slide contained 1024 peptides in
triplicate and used for an in vitro kinase assay on the slide.
In the case of VRK1, two fusion proteins tagged with GST or
His were used, to eliminate potential interference caused by
the tag. In the case of VRK2, the two isoforms (A and B) tagged
with GST were used. The results were highly consistent
among themselves as shown in Fig. 1A.
The different potential phosphorylation targets of VRK
proteins represented as linear peptides are listed in Table 1
where the thirty top scoring proteins from which the peptides
were identified are shown. There is an overlap of substrates
among the four different kinase preparations used. The com-
plete results for each VRK1 and VRK2 preparation as well as
the peptides are shown in Table S2. Coilin appeared to be the
top scoring protein with the four different kinase preparations
(Fig. 1A, circle). The peptide chip identified Ser184 in coilin as
the putative phosphorylated residuewithin the target sequence
(EAKRKSPKKKE) (Fig. 1B). In the list of phosphorylated pep-
tides (Table 1) there are proteins that have different subcellu-
lar localization, ranging from different membranes to the
nucleus. This indicates that perhaps in vivo they are likely to
be phosphorylated when both kinase and substrate are present
within the same subcellular compartment. The degree of simi-
larity between the top scores for each protein, but not identity,
is consistent with the structural differences between VRK1 [38]
and VRK2 [12], as well as with their slightly different sensitivity
to kinase inhibitors [39].
Table 1 – Top thirty proteins identified as potential targets
for each kinase. Those that are common to all of them are
shown in bold.
GST-VRK1 His-VRK1
Coilin Coilin
Bone marrow kinase BMX L1 cell adhesion molecule
L1 cell adhesion molecule Cytohesin 2
TCFL1 Bone marrow kinase BMX
DAB2 DAB2
Cytohesin 2 Ras related protein 1A
Estrogen receptor, alpha Estrogen receptor, alpha
SHP2 Metabotropic glutamate
receptor 1
Vitronectin Ezrin
Complement component 3 High mobility group AT-hook 2
Metabotropic glutamate
receptor 1
SHP2
Neutrophil cytosolic factor 4
40 kDa
Transcription factor IIA, 1
PEA15 Transcription factor HES-1
Ras related protein 1A c-Src
FAK Stathmin 1
Ezrin Cytohesin-1
Cyclin-dependent kinase
inhibitor 1B
Bradykinin receptor 2
Peptidylglycine alpha amidating
monooxygenase
TCFL1
High mobility group AT-hook 2 Neutrophil cytosolic factor 4
40 kDa
Occludin Vitronectin
NIPP1 Bruton's tyrosine kinase
c-Src Adducin 3
eIF2 alpha PLD1
HLA-A Neurogranin
Adducin 1 Calcium channel voltage
dependent beta 2 subunit
Bruton's tyrosine kinase Adducin 1
CCAAT/Enhancer
binding protein, beta
FAK
Bradykinin receptor 2 RAF1
Splicing factor 1 TFII-I
STAT2 Microtubule associated
protein 2
GST-VRK2A GST-VRK2B
Coilin Coilin
Complement component 3 TCFL1
TCFL1 Ezrin
Autoantigen La Autoantigen La
Occludin Bone marrow kinase BMX
L1 cell adhesion molecule Occludin
Eukaryotic translation initiation
factor 4E
Complement component 3
CD5 L1 cell adhesion molecule
Ezrin PEA15
DAB2 DAB2
Bone marrow kinase BMX Syntaxin binding protein 1
Syntaxin binding protein 1 CD5
FAK FAK
Vitronectin Eukaryotic translation initiation
factor 4E
NIPP1 Cytohesin 2
SHP2 Peripherin
Mucin 1 transmembrane Metabotropic glutamate
receptor 1
Peripherin SHP2
Table 1 (continued)
GST-VRK1 His-VRK1
Peptidylglycine alpha amidating Protein phosphatase 1,
regulatory subunit 3A
monooxygenase HOX B7
HOX B7 TFII-I
Caldesmon 1 Vitronectin
Solute carrier family anion
exchange, member 3
ORC1
Protein phosphatase 1,
regulatory subunit 3A
Solute carrier family anion
exchange, member 3
TFII-I Peptidylglycine alpha amidating
Glutamate receptor ionotropic,
N-methyl Daspartatesubunit 2A
monooxygenase
PEA15 Glutamate receptor ionotropic,
N-methyl Daspartate subunit 2A
Metabotropic glutamate
receptor 1
High mobility group AT-hook 2
Ras related protein 1A c-Src
Estrogen receptor, alpha Ras related protein 1A
Bruton's tyrosine kinase
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Using the peptides from the proteins in the topscore lists for
GST-VRK1 and GST-VRK2A, consensus phosphorylation sites
were determined for each of them. Thirty top-scoring pep-
tides were aligned according to the central phosphorylation
site and amino acids were scored in each position. Using a
cutoff at the 95th% percentile of the values the consensus se-
quences were obtained. The consensus target sequence has
several basic residues as shown in Table 2. These results are
consistent with some of the known substrates identified for
VRK1, such as histones [13,15,40]. The detection of basic se-
quences using peptides identifies a group of potential proteins
as substrates, but it will not identify other targets, particularly
those whose specificity is determined by the three dimension-
al structure, as is the case for p53 [13], c-Jun [25] or ATF2 [36].
Phosphorylation of linear peptide substrates may not be a
completely faithful representation of the same peptide se-
quence in the context of a full-length protein.
3.3. Coilin is phosphorylated by VRK1
The top scoring protein in both lists is coilin [41,42]. Therefore,
coilin was selected to test if it is indeed phosphorylated by
VRK1. Coilin (Uniprot: P38432) is a protein present in Cajal bodiesTable 2 – Consensus sequences in proteins identified by
peptide phosphorylation analysis in VRK1 and VRK2
chip-kinase assays. Numbers indicate position relative to
the central S/T or Y, empty positions indicate any amino
acid (standard one letter AA code used).
GST-VRK1
−1 −2 −3 −4 −5 0 +1 +2 +3 +4 +5
K K K K K S R K K K K
R r r y r
GST-VRK2
−1 −2 −3 −4 −5 0 +1 +2 +3 +4 +5
K K K K K S R K D K K
R G S K
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in muscle degenerative diseases [46]. To determine if coilin
could be phosphorylated by VRK1, 293T cells were transfected
with plasmid pCMV6-Myc-DKK-Coilin, and the expressed coilin
was immunoprecipitated and used as substrate of bacterially
expressed GST-VRK1 in the in vitro kinase assay. Both coilin
and p53, used as positive control [24], were phosphorylated
(Fig. 2A). Also the phosphorylation assay was performed using
the two immunoprecipitated proteins, kinase and substrate pre-
pared by transfection in 293T cells, which will permit to use a
more similar equimolar level. HEK293T cells were separately
transfected with either pCFEL-GST-VRK1 or pCMV6-Myc-DKK-
Coilin. VRK1 was prepared by a GST-pulldown, and coilin by
and anti myc epitope immunoprecipitation. The kinase assay
was carried out mixing equal amounts of immunoprecipitated
and pull-downed proteins (Fig. 2B). The peptide chip identified
Ser184 in coilin as the putative phosphorylated residue within
the target sequence (EAKRKSPKKKE). This residue was substitut-
ed to alanine and tested in a kinase assay. However, coilin was
still phosphorylated suggesting that several residues are phos-
phorylated by VRK1 in coilin. Coilin has eighteen residues
phosphorylated by unknown kinases [47], out of total of forty-Fig. 2 – Phosphorylation of coilin by humanVRK1. A. Coilin-myc (pC
with an anti-myc antibody in the presence of 500mMNaCl to reduc
vitro kinase assay with bacterially expressed GST-VRK1 and GST-p5
kinase assay is shown at the top. In themiddle is the stainingwith P
bottom is shown the transfected coilin detected with an anti myc an
phosphorylates coilin inmore than one residue. The kinase assay w
with a GST-VRK1 preparation using a mammalian expression const
forms of coilin were used, wild-type and a Coilin S184Amutant. C. P
Phosphoaminoacid analysiswas performed byhigh-voltage electrop
right.seven potentially phosphorylated amino acids (Phospho-ELM
database).
To identify the residues phosphorylated a phosphoami-
noacid analysis was performed with immunoprecipitated
coilin-myc or coilin-S184A-myc. Both proteins were phos-
phorylated in Ser and Thr residues (Fig. 2C, left). Taking the
Thr residue as two, there were at least six serines phosphory-
lated in the wild type coilin and something less in the Ser184
mutant. Thus a minimum of three residues can be phosphor-
ylated by VRK1 in coilin, and one of them is likely to be Ser184,
since when mutated there is a relative reduction in its signal
(Fig. 2C, right). Phosphopeptide analysis did not permit the
identification of Ser184 phosphorylation, because this residue
is within a lysine rich region and flanked by several sequences
recognized by trypsin, which did not permit identification of
the peptide containing this residue (Fig. S1).
3.4. Colocalization between VRK1 and coilin in Cajal bodies
VRK1 is a very abundant nuclear protein that it is likely to form
protein complexes based on its granular appearance [8]. There-
fore, it was tested if endogenous VRK1 might colocalize withMV6-coil) was transfected in 293T cells and immunoprecipitated
e background. The coilin immunoprecipitate was used for an in
3(1–53) was used as positive control of phosphorylation. The
onceau to detect the bacterially expressed proteins used. At the
tibody in the immunoprecipitate used as substrate. B. VRK1
as performed using transfected and immunoprecipitated coilin,
ruct purified by pulldownwith Glutathione–Sepharose. Two
hosphoaminoacid analysis of coilin phosphorylated by VRK1.
horesis. The quantification and relative values are shown to the
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[44]. Coilin appears located in well-defined Cajal bodies in HeLa
cells detected by confocal microscopy. The coilin fluorescence
signal completely overlaps with that of VRK1 (Fig. 3), and sug-
gested that the two proteins might interact at this particular lo-
cation in Cajal bodies. However, this colocalization is likely to
involve only a minor subpopulation of VRK1 protein, which is
muchmore abundant and located throughout the nucleus [8,35],
3.5. Direct interaction between VRK1 and coilin
The direct interaction between VRK1 and coilin was tested in
GST pulldown assay with VRK1 or its kinase-dead mutant
(K179E) in cells transfectedwith coilin-myc. Coilin was detected
in the pull down bound to both forms of VRK1 (Fig. 4A). Next, to
show that endogenous VRK1 was also interacting with coilin, a
reciprocal immunoprecipitation was performed in HeLa cells
transfectedwith coilin-myc, to compensate for its comparative-
ly much lower level of expression. The coilin immunoprecipi-
tate also contained endogenous VRK1 (Fig. 4B). Also in the
immunoprecipitate of endogenous VRK1 was detected the
transfected coilin (Fig. 4C). Thus, we concluded that VRK1 and
coilin can directly interact, and both probably form part of a
common protein complex located in nuclear Cajal bodies.
3.6. The VRK1 (R358X) mutant localizes to the cytosol
Recently the first humanmutation in VRK1was detected associ-
ated to a complexneurological diseasewithapontocerebellar de-
generation andmuscular atrophy [34]. The mutant VRK1(R358X)
has a mutation within its NLS (nuclear localization signal) and
thus differs in its C terminal region from VRK1, since it lacks
the last 38 carboxy-terminal amino acids. This suggests that in
cells, the VRK1(R358X) mutant protein is likely to be located in
the cytosol. To test this possibility HEK293T and Hela cells were
transfected with plasmids expressing either wild-type VRK1 or
the VRK1(R358X) mutant both tagged with the HA epitope. TheFig. 3 – Colocalization of VRK1 and coilin. A. Colocalization of end
cells detected by confocal microscopy. VRK1 was detected with a
monoclonal antibody Pdelta from Abcam.wild-type VRK1 is located in the nucleus, but the VRK1(R385X)
mutant protein is located in the cytosol as detected by immuno-
fluorescence confocalmicroscopy (Fig. 5A). In both cell lines, coi-
lin is detected in the nuclear Cajal bodies and colocalization is
only detected with wild-type VRK1, but not with VRK1(R358X)
(Fig. 5A). This suggests that due to its different localization coilin
cannot be a target of the mutant VRK1(R358X).
The previous results do not rule out that VRK1(R358X) has
lost its potential interaction with coilin. To test this possibility,
cells were transfected with coilin, and the lysates mixed with
bacterially expressed GST-VRK1 and GST-VRK1(R358X) pro-
teins. Both proteins were able to bring down coilin (Fig. 5B),
thus the mutant has not lost its ability to interact with coilin.
Next, the biochemical properties of themutant VRK1(R358X)
with respect the normal VRK1 protein were characterized in an
in vitro kinase assay using autophosphorylation and phosphor-
ylation of known substrates, such as histone H3 [15,40], c-Jun
[25], ATF2 [36], and p53 [8,13,28] and coilin. VRK1(R358X) is ap-
proximately eightfold less active than VRK1, however both
seem to have the same substrate specificity. All substrates
were similarly phosphorylated, taking into account the activity
of each protein in autophosphorylation (Fig. 6A). The reduced
kinase activity of mutant VRK1(R358X) was also determined
using bacterially expressed proteins with a His tag (Fig. S2A)
or expressed in HEK293T cells, from which they were immuno-
precipitated and used for a kinase assay (Fig. S2B).
The normal VRK1 protein is very stable [26], but the VRK1
(R358X) protein was not detectable in patients and this was
apparently due to nonsense-mediated decay [34], this would
predict that both proteins are likely to have a similar stability.
To confirm this property, both VRK1 and VRK1(R358X) were
transiently transfected in HEK-293T cells and their stability
determined at different time points after cycloheximide addi-
tion, using the unstable kinase-dead form of VRK1(K179E) as
control [26]. All proteins were equally expressed, and VRK1
and VRK1(R358X) appeared to have a similar stability (Fig. S3),
while the kinase-dead was more unstable as expected [26].ogenous VRK1 and endogenous coilin in Cajal bodies of HeLa
polyclonal antibody from Sigma. Coilin was detected with the
Fig. 4 – Direct interaction between VRK1 and coilin. A. GST pull-down with VRK1 or VRK1KD (kinase dead: K179E). GST-VRK1,
GST-VRK1KD and empty GST plasmids were transfected in HEK293T cells in combination with coilin-myc. Lysates weremixed
with Glutathione Sepharose beads. Precipitated proteins were detected with anti-GST and anti-myc antibodies.
B. Immunoprecipitation of coilin-myc and detection of endogenous VRK1 in the immunoprecipitate. HEK-293T cells were
transfected with 5 μg of plasmid pCMV6-Myc-DKK-coilin (coilin-myc) or empty vector. The lysates were immunoprecipitated
with anti-myc antibody. Immunoprecipitated coilin-myc was detected with anti-myc and VRK1 with polyclonal anti-VRK1
(Sigma). C. Immunoprecipitation of endogenous VRK1 and detection of coilin in the immunoprecipitate. HEK293T cells were
transfected with 5 μg of plasmid pCMV6-Myc-DKK-coilin (coilin-myc). The lysates were used for immunoprecipitation of
endogenous VRK1 with a mixture of polyclonal αVRK1 (Sigma) against amino terminal region, and polyclonal αVRK1 ‘VC’
against carboxy terminal region [35]. The proteins in the immunoprecipitate are shown at the top.
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that modulates kinase activity [38] and might affect protein
interactions or recognition by antibodies. The mutant VRK1
(R358X) has a mutation within its NLS (nuclear localization
signal) and thus differs in its carboxy terminal region from
VRK1, since it lacks the terminal 38 amino acids. VRK1 is rec-
ognized by different antibodies which have a different reactiv-
ity [35]. The antibodies were tested on both proteins. All
polyclonal antibodies, VE1, VC1 [35] and anti-VRK1 (Sigma),
equally recognize normal and mutant protein (Fig. S4). But
there was differential recognition by the monoclonal anti-
bodies that recognize an epitope proximal to the NLS [35].
While mAb 1B5 recognizes both proteins, 1F6 did not recog-
nize the mutant R358X (Fig. S4).
3.7. Allele specific expression and transcript stability of
VRK1 and VRK1(R358X)
However in affected individuals the VRK1(R358X) mutation,
the mutant protein might be deleterious and not expressed
or eliminated; in both cases the consequence will be the loss
of coilin phosphorylation, and functionally is the equivalent
of a VRK1 knockdown. To determine if the mutant VRK1 allele
is expressed, EBV immortalized lymphocytes from a heterozy-
gous carrier were used for detection of VRK1 RNA expression.
VRK1 exons 8 and 12 were sequenced in both genomic DNA
and cDNA from a R358X carrier (wt/R358X). Genomic DNA
and cDNA were extracted from an EBV-transformed B cell
line with and without puromycin treatment (Fig. 7). In this in-
dividual there is a known exon 8 C>T SNP (rs2230532) that is
in cis with the exon 12 R358X (1072 C>T) mutation, and serves
as an additional marker for nonsense mediated decay (NMD).Genomic DNA sequences (left) show equal biallelic expression
of both exon 8 and exon 12 sequences. cDNA from untreated
cells (middle) shows highly biased allelic expression (wild-
type allele predominates over the mutant by >80%). cDNA
extracted from cells treated with the translation inhibitor pu-
romycin for 8.5 h (100 μM, right) shows restored expression of
the mutant allele, to levels almost equal to those of the wild-
type. This result indicates that the mutant protein is not pre-
sent in cells from the heterozygous mutation carrier.4. Discussion
The use of peptide arrays to identify kinase substrates led to
the identification of several proteins with a basic motif as po-
tentially targeted by human VRK1 and VRK2 proteins. These
results are consistent with some of the known substrates
identified for VRK1, which are not in signaling pathways.
Human VRK1 phosphorylates histone H2B and MBP (myelin
basic protein) in vitro [13] and histone H3 in vitro [15] and in
vivo [40]. Also NHK-1, the Drosophila melanogaster unique
ortholog, phosphorylates histone H2A [48]. The detection of
basic sequences using peptides identifies a group of potential
proteins as substrates, but it will not identify other targets,
particularly those in which the specificity is determined by
the three dimensional structure of the protein, as is the case
for p53 [13], c-Jun [25] or ATF2 [36], and also a VRK1 autopho-
sphorylation site in a Ser355 preceding its canonical and
basic nuclear localization signal [24]. Up to now, no kinase
showing a bias towards basic sequences, where the introduc-
tion of a negative charge can significantly distort the local
charge, has been identified. This negative charge in basic
Fig. 5 – Subcellular localization and characterization of the mutant VRK1(R358X). A. Subcellular localization of HA-VRK1,
HA-VRK1(R358X) and coilin. 293T cells were transfected with 0.5 μg of plasmid HA-VRK1 or HA-VRK1(R358X), and HeLa cells
were transfected with 2 μg of plasmids. Cells were fixed and the localization of the proteins was analyzed by confocal
microscopy. Transfected proteins were detected with αHA polyclonal antibody, and endogenous coilin with the monoclonal
antibody Pdelta. Bars indicate 10 μm. B. Interaction of coilin-myc with GST-VRK1 and GST-VRK1(R358X). GST-VRK1 (WT) and
GST-VRK1(R358X) (RX) were expressed and purified from E. coli and 5 μg of proteins bound to Glutathione Sepharose beads
was added and incubated overnight to HEK-293T extracts overexpressing coilin-myc. Coilin-myc was detected in the
precipitates with an α-myc antibody.
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Fig. 6 – Characterization of the mutant VRK1(R358X). A. Kinase assays with purified GST-VRK1 and GST-VRK1(R358X)
proteins. Assays were performed with the following VRK1 established substrates: histone H3, GST-cJun, GST-ATF2
(aa 1–84) and GST-p53 (aa 11–63). GST protein was used as negative control. Phosphorylation of these substrates, as well
as VRK1 autophosphorylation was detected. Autoradiographies (32P) and Coomassie blue staining are shown.
B-F. Quantification of the levels of VRK1 autophosphorylation (B) and phosphorylation of substrates (C–F). Graphs show the
relative levels of 32P incorporation. The average of the five blots is represented for VRK1 autophosphorylation in B. Bars
indicate standard deviation. G. VRK1(R358X) can phosphorylate coilin in vitro but to a lesser extent than VRK1 wild type.
Left. Coilin-myc was transfected in HEK-293T cells and purified from cell extracts by immunoprecipitation with an
anti-myc antibody. Immunoprecipitated coilin-myc was used as substrate in a kinase assay with bacterially expressed
GST-VRK1 and GST-VRK1(R358X) (RX). Right. Quantification of the levels of coilin-myc phosphorylation by GST-VRK1 and
GST-VRK1(R358X).
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or protein–DNA interactions. Because peptides are linear se-
quences the approach used may not identify all the potential
substrate of a particular kinase. Also substrates might be
missed if they depended on a particular protein conformation
or interaction affecting one of the partners, substrate or ki-
nase. Nevertheless the approach is useful to identify a group
of substrates as demonstrated for Raf kinase [22].
Among the substrates identified common to the three VRK
enzymes it is worth to call the attention to coilin. Coilin is a pro-
tein mainly detected in nuclear particles known as Cajal bodies,
which participate in RNA processing. Coilin can be in a disas-
sembled form or in aggregates forming Cajal bodies, the regula-
tion of the transition between these two states is regulated by
phosphorylation [45], but the signaling pathway regulating this
transition is unknown. Coilin is hyperphosphorylated in at
least eighteen residues, which is consistent with the multipho-
sphorylation mediated by VRK1, and thus makes this kinase alikely regulatory element in Cajal body assembly. Coilin phos-
phorylation is necessary for Cajal body assembly [42,45]. In addi-
tion there is a specific phosphorylation site of Ser184 in coilin,
that has been proposed to be phosphorylated by CDK2/CycE
[41], and to which VRK1 has to be added, but the significance of
this site-specific phosphorylation is not yet known. Protein
phosphorylation can also regulate protein–protein interactions,
and thismight be another of the roles played by coilin phosphor-
ylationmediated byVRK1. Among coilin interaction partners are
ataxin 1 (ATX1) [33] and SMN (survival motor neuron protein)
[46]. ATX1 is a protein that when defective in humans causes
ataxia and spinal muscular dystrophy [49] and its interactions
are regulated by phosphorylation [50]; and SMN involved in spi-
nalmuscular atrophy [46]. Interestingly, VCP (valosin containing
protein), another protein interacting with and phosphorylated
byVRK1 (unpublished), is also associatedwith somemyopathies
[51]. A subpopulation of VCP is located in the nucleus and forms
hyaline inclusion bodies in motor neurons of patients with
Fig. 7 – Allele-specific expression of VRK1 in R358X carriers.
VRK1 exons 8 and 12 were sequenced in both genomic DNA
and cDNA from a R358X carrier (wt/R358X). Genomic DNA and
cDNAwere extracted from an EBV-transformed B cell line with
and without puromycin treatment. In this individual a known
exon 8 C>T SNP (rs2230532) is in ciswith the exon 12 R358X
(s C>T) mutation and serves as an additional marker for NMD.
Genomic DNA sequences (left) show equal biallelic expression
of both exon 8 and exon 12 sequences. cDNA from untreated
cells (middle) showshighly biased allelic expression (wild-type
allele predominates over themutant by >80%). cDNA extracted
from cells treated with the translation inhibitor puromycin for
8.5 h (100μM, right) shows restored expression of the mutant
allele, to levels almost equal to those of the wild-type. The
arrows indicate the position of the nucleotide substitutions,
polymorphism or mutation.
558 J O U R N A L O F P R O T E O M I C S 7 5 ( 2 0 1 1 ) 5 4 8 – 5 6 0amyotrophic lateral sclerosis [52]; and also in Lewis bodies found
in Parkinson patients [52–54]. The consequence is that in these
patients coilin regulation by phosphorylation is defective and
thus coilin interactions with other proteins, such as SMN1,
Sm, or ATX1 might be altered and account for the syndrome
observed in these patients. Coilin phosphorylation modu-
lates the selection of interacting protein; phosphorylated coi-
lin preferentially binds to Sm, while dephosphorylated coilin
interacts with SMN1 [32]. All these proteins are associated
with some forms of ataxia andmuscular atrophy. The central
role of coilin in several neuropathological syndromes, makes
its regulatory proteins, of which VRK1 is one of them, likely
candidates for their alteration and implication in the patho-
genesis of specific syndromes by altering the phosphoryla-
tion of coilin, and thus its regulation and protein interactions.
Recently a human mutant form of VRK1 has been identified,
characterized by a termination codon and generating a truncated
protein, that in homozygosis causes a spinocerebellar muscular
atrophy syndrome [34]. The loss of VRK1(R358X) mutant protein
means that in cells it cannot phosphorylate its target coilin pro-
tein, because they are in different compartments. In this patient
there is expressionof themutatedallele, but its RNA is eliminated
by nonsense-mediated decay. In addition to its mislocalization
and low levels, the VRK1(R358X) mutant is less active as kinase,this is due to the loss of its C-terminal region which is required
for the proper conformation of the active site [38]. The conse-
quences of mutations in the VRK1 C-terminal region may vary
due to the role of this C-tail in controlling the kinase activity
[38], as well as by loss of protein–protein interaction [15]. In het-
erozygous individuals the consequence of the R358X mutation
are notmanifested because they are compensated by the normal
allele. In homozygous R358X cases, some of the VRK1functions,
such as those related with cell cycle might be compensated,
while those implicated in more specialized functions, like neu-
rological ones, might contribute to the observed phenotype
[34]. . Two partners of coilin, ataxin1 mutated in ataxias [55]
and SMN1 mutated in muscular atrophy [56], partially share
their neurological phenotype with the VRK1 mutation [34]. It is
likely that different situations might become detectable, when
searched for, in neurological syndromes where VRK1 might be
a candidate mutated gene in their unknown pathogenesis
It is also interesting to note that in a murine gene-trap par-
tial knockout model of VRK1, there is a 15% residual VRK1 that
might prevent manifestation of other aspects of the pheno-
type, the resulting phenotype is mice sterility due to meiotic
defects [57–59], but in these animals neurological symptoms
were not studied and curiously the knockout of coilin also re-
sults in mice sterility [60]. The biological role and significance
of VRK proteins in coilin dynamics are an area requiring fur-
ther studies because of their potential clinical implications
in oncology and neurology.
In this report we have identified that VRK1 interacts and
phosphorylates coilin, a protein regulating the assembly of
Cajal bodies in the nucleus. The role of VRK1 in coilin phos-
phorylation opens up several new avenues for research in
major neurological disorders, such as muscular atrophy,
amyotrophic lateral sclerosis, Parkinson disease and ataxias,
among others, which needs to be studied in patients with can-
didate neuropathology.
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